---
title: "Xizang Mineral released its performance for the first three quarters, with a net loss attributable to the parent company of 7.2174 million yuan"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/263099501.md"
description: "According to the Zhitong Finance APP, Xizang Mineral released its third-quarter report for 2025. In the first three quarters, the company achieved operating revenue of 203 million yuan, a year-on-year decrease of 65.45%. The net loss attributable to shareholders of the listed company was 7.2174 million yuan. The net loss attributable to shareholders of the listed company after deducting non-recurring gains and losses was 19.4893 million yuan"
datetime: "2025-10-28T13:12:05.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/263099501.md)
  - [en](https://longbridge.com/en/news/263099501.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/263099501.md)
generator: "portal-rs"
---

# Xizang Mineral released its performance for the first three quarters, with a net loss attributable to the parent company of 7.2174 million yuan

According to the Zhitong Finance APP, Xizang Mineral (000762.SZ) released its third-quarter report for 2025. In the first three quarters, the company achieved an operating income of 203 million yuan, a year-on-year decrease of 65.45%. The net loss attributable to shareholders of the listed company was 7.2174 million yuan. The net loss attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 19.4893 million yuan

### Related Stocks

- [000762.CN](https://longbridge.com/en/quote/000762.CN.md)

## Related News & Research

- [Greenland Mines Ltd trading halted, news pending](https://longbridge.com/en/news/296671630.md)
- [SSF Records RM10.55 Million PAT for FYE2026](https://longbridge.com/en/news/296720898.md)
- [06:56 ETTTW Announces the Top 50 Travel Solution Cards in the World for 2026](https://longbridge.com/en/news/296700759.md)
- [Orum Therapeutics Announces U.S. FDA Clearance of an IND Application for ORM-1153, a Novel CD123-GSPT1 Degrader-Antibody Conjugate](https://longbridge.com/en/news/296689195.md)
- [NRED Identifies Stronger Untested IP Targets Beyond 1.67% Copper Trench Mineralization at Wilmac | NREDF Stock News](https://longbridge.com/en/news/296612079.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**